Skip to main content
Erschienen in: International Journal of Hematology 1/2017

03.10.2016 | Original Article

Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study

verfasst von: A. M. Yesilova, S. Yavuzer, H. Yavuzer, M. Cengiz, I. D. Toprak, E. Hanedar, M. C. Ar, Z. Baslar

Erschienen in: International Journal of Hematology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

The aims of this study are to determine the incidence and risk factors of thrombosis and bleeding in polycythemia vera (PV) patients and to research the effects of these risk factors on survival. The medical records of 155 PV patients were analyzed retrospectively. Patients were divided into groups according to whether or not thrombosis had developed in follow-up, and according to whether or not bleeding had occurred during follow-up. The mean age at diagnosis was 53 years, and the mean follow-up period was 66 months. The percentage of cases in which thrombosis events had occurred before diagnosis and during follow-up were 26 and 28 %, respectively. Comparisons of disease duration and average thrombosis risk score between groups with or without thrombosis drew statistically significant results. A patient’s history of thrombosis and thrombocytosis at first visit was found to have a significant effect on thrombosis recurrence. The major bleeding rate was 8 %. Post-PV myelofibrosis was an independent risk factor for bleeding. The major cause of death among the patients in this study was primary thrombosis. The most important causes of mortality among PV patients are thrombosis, and the most prominent risk factors for thrombosis development are disease duration and high thrombosis risk scores. Thrombocytosis in patients with a history of thrombosis may cause thrombosis recurrence during the follow-up period.
Literatur
1.
Zurück zum Zitat Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–90.CrossRefPubMed Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275–90.CrossRefPubMed
2.
Zurück zum Zitat Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995;123(9):656–64.CrossRef Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Intern Med. 1995;123(9):656–64.CrossRef
3.
Zurück zum Zitat Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2V617F mutation status. Haematologica. 2007;92(1):135–6.CrossRefPubMed Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2V617F mutation status. Haematologica. 2007;92(1):135–6.CrossRefPubMed
4.
Zurück zum Zitat Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162–73 (Erratum in: Am J Hematol. 2015 Sep;90(9):849).CrossRefPubMed Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90(2):162–73 (Erratum in: Am J Hematol. 2015 Sep;90(9):849).CrossRefPubMed
5.
Zurück zum Zitat Lim Y, Lee JO, Kim SH, Kim JW, Kim YJ, Lee KW, et al. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thromb Res. 2015;135(5):846–51.CrossRefPubMed Lim Y, Lee JO, Kim SH, Kim JW, Kim YJ, Lee KW, et al. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thromb Res. 2015;135(5):846–51.CrossRefPubMed
6.
Zurück zum Zitat Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl JMed. 2013;368(1):22–33.CrossRef Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl JMed. 2013;368(1):22–33.CrossRef
7.
Zurück zum Zitat Landolfi R, DiGennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93(3):331–5.CrossRefPubMed Landolfi R, DiGennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica. 2008;93(3):331–5.CrossRefPubMed
8.
Zurück zum Zitat Kander EM, Raza S, Zhou Z, Gao J, Zakarija A, McMahon BJ, et al. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol. 2015;102(5):587–93.CrossRefPubMed Kander EM, Raza S, Zhou Z, Gao J, Zakarija A, McMahon BJ, et al. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. Int J Hematol. 2015;102(5):587–93.CrossRefPubMed
9.
Zurück zum Zitat Budde U, vanGenderen PJ. Acquired vonWillebrand disease in patients with high platelet counts. Semin Thromb Hemost. 1997;23(5):425–31.CrossRefPubMed Budde U, vanGenderen PJ. Acquired vonWillebrand disease in patients with high platelet counts. Semin Thromb Hemost. 1997;23(5):425–31.CrossRefPubMed
10.
Zurück zum Zitat Pearson TC, Messinezy M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma. 1996;22(11):87–93.PubMed Pearson TC, Messinezy M. The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma. 1996;22(11):87–93.PubMed
11.
Zurück zum Zitat Thiele J, Kvasnicka HM. [Chronic myeloproliferative disorders. The new WHO classification]. Pathologe. 2001;22(6):429–43.CrossRefPubMed Thiele J, Kvasnicka HM. [Chronic myeloproliferative disorders. The new WHO classification]. Pathologe. 2001;22(6):429–43.CrossRefPubMed
12.
Zurück zum Zitat Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14–22.CrossRefPubMed Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14–22.CrossRefPubMed
13.
Zurück zum Zitat Skoda R. The genetic basis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2007;1–10. Skoda R. The genetic basis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2007;1–10.
14.
Zurück zum Zitat Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128–38.CrossRefPubMedPubMedCentral Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128–38.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124(19):3021–3.CrossRefPubMed Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124(19):3021–3.CrossRefPubMed
16.
Zurück zum Zitat Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.CrossRefPubMed Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224–32.CrossRefPubMed
17.
Zurück zum Zitat Crisà E, Venturino E, Passera R, Prina M, Schinco P, Borchiellini A, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691–9.CrossRefPubMed Crisà E, Venturino E, Passera R, Prina M, Schinco P, Borchiellini A, et al. A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010;89(7):691–9.CrossRefPubMed
18.
Zurück zum Zitat Denninger MH, Chaït Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal orhepaticvenousthrombosis inadults: the role of multipleconcurrentfactors. Hepatology. 2000;31(3):587–91.CrossRefPubMed Denninger MH, Chaït Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Erlinger S, Briere J, Valla D. Cause of portal orhepaticvenousthrombosis inadults: the role of multipleconcurrentfactors. Hepatology. 2000;31(3):587–91.CrossRefPubMed
19.
Zurück zum Zitat Cardin F, Graffeo M, McCormick PA, McIntyre N, Burroughs A. Adult, “idiopathic” extrahepatic venous thrombosis. Importance of putative “latent” myeloproliferative disorders and comparison with cases with known etiology. Dig Dis Sci. 1992;37(3):335–9.CrossRefPubMed Cardin F, Graffeo M, McCormick PA, McIntyre N, Burroughs A. Adult, “idiopathic” extrahepatic venous thrombosis. Importance of putative “latent” myeloproliferative disorders and comparison with cases with known etiology. Dig Dis Sci. 1992;37(3):335–9.CrossRefPubMed
20.
Zurück zum Zitat Bazzan M, Tamponi G, Schinco P, Vaccarino A, Foli C, Gallone G, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol. 1999;78(12):539–43.CrossRefPubMed Bazzan M, Tamponi G, Schinco P, Vaccarino A, Foli C, Gallone G, et al. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia. Ann Hematol. 1999;78(12):539–43.CrossRefPubMed
21.
Zurück zum Zitat Varma S, Sharma A, Malhotra P, Kumari S, Jain S, Varma N. Thrombotic complications of polycythemia vera. Hematology. 2008;13(6):319–23.CrossRefPubMed Varma S, Sharma A, Malhotra P, Kumari S, Jain S, Varma N. Thrombotic complications of polycythemia vera. Hematology. 2008;13(6):319–23.CrossRefPubMed
22.
Zurück zum Zitat De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372–80.CrossRefPubMed De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93(3):372–80.CrossRefPubMed
23.
Zurück zum Zitat Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446–52.CrossRefPubMed Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109(6):2446–52.CrossRefPubMed
24.
Zurück zum Zitat Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol. 2002;29(3):16–21.CrossRefPubMed Pearson TC. The risk of thrombosis in essential thrombocythemia and polycythemia vera. Semin Oncol. 2002;29(3):16–21.CrossRefPubMed
25.
Zurück zum Zitat Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, et al. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136(2):249–59.CrossRefPubMed Di Nisio M, Barbui T, Di Gennaro L, Borrelli G, Finazzi G, Landolfi R, et al. European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP) Investigators. The haematocrit and platelet target in polycythemia vera. Br J Haematol. 2007;136(2):249–59.CrossRefPubMed
27.
Zurück zum Zitat Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015;126(13):1551–4.CrossRefPubMedPubMedCentral Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood. 2015;126(13):1551–4.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Vannucchi AM. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(17):1670–1.CrossRefPubMed Vannucchi AM. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372(17):1670–1.CrossRefPubMed
29.
Zurück zum Zitat Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–24.CrossRefPubMed Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–24.CrossRefPubMed
30.
Zurück zum Zitat Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007;109(12):5104–11.CrossRefPubMed Finazzi G, Barbui T. How I treat patients with polycythemia vera. Blood. 2007;109(12):5104–11.CrossRefPubMed
31.
Zurück zum Zitat Tefferi A, Barbui T. New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. Am J Hematol. 2015;90(8):683–5.CrossRefPubMed Tefferi A, Barbui T. New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera. Am J Hematol. 2015;90(8):683–5.CrossRefPubMed
32.
Zurück zum Zitat Chıevıtz E, Thıede T. Complications and causes of death in polycythaemia vera. Acta Med Scand. 1962;172:513–23.PubMed Chıevıtz E, Thıede T. Complications and causes of death in polycythaemia vera. Acta Med Scand. 1962;172:513–23.PubMed
33.
Zurück zum Zitat Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304(8):441–7.CrossRefPubMed Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med. 1981;304(8):441–7.CrossRefPubMed
Metadaten
Titel
Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study
verfasst von
A. M. Yesilova
S. Yavuzer
H. Yavuzer
M. Cengiz
I. D. Toprak
E. Hanedar
M. C. Ar
Z. Baslar
Publikationsdatum
03.10.2016
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 1/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2105-0

Weitere Artikel der Ausgabe 1/2017

International Journal of Hematology 1/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.